Pharmaceutical Business review

Ipsen’s Adenuric obtains European marketing authorization

Adenuric (febuxostat) 80mg and 120mg tablets are indicated for the treatment of chronic hyperuricaemia for conditions in which urate deposition has already occurred (including a history, or presence of, tophus and/or gouty arthritis).

Adenuric will be marketed by Ipsen in France. Outside France, the commercialization of the product will be partnered.